$BIOA earnings report

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates. AlphAI read BioAge Labs's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readBIOA · Third Quarter 2026 · ended September 30, 2026

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

→Mixed quarter

BioAge advanced BGE-102 through enrollment completion in QUELL-CV and first-patient dosing in QUELL-DME, while ending the quarter with approximately $352.3 million in cash, cash equivalents, and marketable securities and estimated funding through 2029. Financial results reflected sharply higher BGE-102 clinical and manufacturing spending, lower collaboration revenue, and a wider net loss.

Revenue
$300K
$1.8 million decrease y/y
Collaboration revenue
$300K
$1.8 million decrease y/y
EPS · GAAP
$0.73

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Collaboration revenueGAAP$300K–$1.8 million decrease
Research and development expensesGAAP$30.2M–$11.7 million increase
General and administrative expensesGAAP$7.5M–$0.8 million increase
Total operating expensesGAAP37,709––
Loss from operationsGAAP(37,411)––
Interest expenseGAAP—––
Interest and other income (expense), netGAAP3,393––
Gain (loss) from changes in fair value of warrantsGAAP514––
Total other income (expense), netGAAP3,907––
Net lossGAAP$33.5M––
Net loss per share attributable to common stockholders, basic and dilutedGAAP$0.73––
Weighted-average common shares outstanding, basic and dilutedGAAP45,911,481––

Segments

SegmentRevenueq/qy/y
Collaboration revenueThe decrease was primarily due to a $1.7 million cumulative catch-up adjustment recorded in connection with a September 2026 amendment to the Novartis Agreement, which added $0.9 million of research funding and expanded the research activities to be performed.$300K–$1.8 million decrease

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Fourth quarter of 2026, year-end 2026, second half of 2027, and through 2029 outlook

  • NoteTopline data from QUELL-CV are anticipated in the fourth quarter of 2026.
  • NoteThe Company intends to file its first IND for an APJ program by year-end 2026.
  • NoteTopline results from QUELL-DME are anticipated in the second half of 2027.
  • NoteBioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.

What drove it

  • QUELL-CV completed enrollment of approximately 160 participants and topline data are anticipated in the fourth quarter of 2026.
  • The first participant was dosed in QUELL-DME in September 2026; the approximately 180-participant trial has topline results anticipated in the second half of 2027.
  • Research and development expense increased primarily because of a $13.2 million increase in BGE-102 direct costs related to QUELL-CV and QUELL-DME clinical trial costs and drug product manufacturing costs.
  • Research and development expense was also driven by a $1.7 million increase in personnel-related expenses from increased headcount and higher stock-based compensation expense.
  • The Deep Origin collaboration reached its first milestone in October 2026, with computationally identified hits validated in BioAge's laboratory.

Concerns

  • Collaboration revenue declined due primarily to a $1.7 million cumulative catch-up adjustment associated with the September 2026 Novartis Agreement amendment.
  • Net loss widened to $33.5 million from $20.2 million as research and development expenses increased to support BGE-102 clinical development and manufacturing.
  • QUELL-DME topline results are not anticipated until the second half of 2027.
  • The release identifies risks associated with clinical trials, unexpected concerns from additional data or analysis, regulatory approvals, and the ability to manage clinical activities for BGE-102 and APJ programs.

What to watch

  • QUELL-CV topline data anticipated in the fourth quarter of 2026, including percent change from baseline in hsCRP over 12 weeks of dosing.
  • The intended first IND filing for an APJ program by year-end 2026.
  • QUELL-DME progress toward topline results anticipated in the second half of 2027, with change from baseline in best-corrected visual acuity at week 12 as the primary endpoint.
  • The pace of BGE-102 clinical trial and drug product manufacturing costs.
  • Progress of the Novartis, Lilly ExploR&D, and Deep Origin collaborations.

Balance sheet and cash flow

  • Cash and cash equivalents were $52,666 as of September 30, 2026, compared to $188,888 as of December 31, 2025.
  • Marketable securities, current were $230,971 as of September 30, 2026, compared to $92,210 as of December 31, 2025.
  • Marketable securities were $68,680 as of September 30, 2026, compared to $4,032 as of December 31, 2025.
  • Cash, cash equivalents, and marketable securities were approximately $352.3 million as of September 30, 2026.
  • Current portion of term loan was — as of September 30, 2026, compared to 2,648 as of December 31, 2025.
  • Total assets were $367,648 as of September 30, 2026, compared to $294,889 as of December 31, 2025.
  • Total liabilities were 21,202 as of September 30, 2026, compared to 22,838 as of December 31, 2025.
  • Total stockholders’ equity was 346,446 as of September 30, 2026, compared to 272,051 as of December 31, 2025.

Analysis

BioAge's third-quarter update was defined by clinical execution rather than commercial revenue. QUELL-CV completed enrollment of approximately 160 participants, with topline data anticipated in the fourth quarter of 2026. The company also dosed the first participant in QUELL-DME during September 2026. That approximately 180-participant study evaluates BGE-102 as monotherapy and with anti-VEGF therapy, with topline results anticipated in the second half of 2027. The APJ agonist program remains targeted for a first IND filing by year-end 2026.

Financial results show a marked increase in development spending. Research and development expenses rose to $30.2 million from $18.5 million, primarily reflecting a $13.2 million increase in BGE-102 direct costs for QUELL-CV and QUELL-DME clinical work and drug product manufacturing. A $1.7 million increase in personnel-related expenses also contributed. General and administrative expenses increased to $7.5 million from $6.7 million, led by higher stock-based compensation and consulting fees. Net loss widened to $33.5 million, or $0.73 per weighted-average common share outstanding, basic and diluted, from $20.2 million, or $0.56 per weighted-average common share outstanding, basic and diluted.

Collaboration revenue declined to $0.3 million from $2.1 million. The company attributed the $1.8 million decrease primarily to a $1.7 million cumulative catch-up adjustment related to a September 2026 amendment to the Novartis Agreement. The amendment added $0.9 million of research funding and expanded the research activities to be performed, increasing the total estimated effort required to satisfy the performance obligation. This revenue movement is therefore tied to accounting for the amended collaboration rather than a disclosed change in the underlying clinical pipeline.

Liquidity remains a central support for the development plan. BioAge reported approximately $352.3 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and estimates that these resources will fund operations and capital expenses through 2029. Cash and cash equivalents were $52,666, while current and noncurrent marketable securities were $230,971 and $68,680, respectively. The current portion of the term loan was reported as — at September 30, 2026, compared with 2,648 at December 31, 2025.

The next material operating event is the anticipated fourth-quarter 2026 QUELL-CV readout. Its primary endpoint is percent change from baseline in hsCRP over 12 weeks, and the trial is intended to characterize the BGE-102 dose-response relationship and support dose selection for further development. Longer term, investors will focus on the APJ IND timing, the progression of QUELL-DME, and whether the company can manage the higher clinical and manufacturing cost base while advancing its multiple early-stage programs.

Management, verbatim

BGE-102 has a potential best-in-class profile: in Phase 1, it suppressed IL-1β by up to 98% with once-daily dosing and was well tolerated.

Kristen Fortney, Ph.D., CEO and co-founder of BioAge

Our Phase 2 cardiovascular study, QUELL-CV, is fully enrolled, and we expect the results later this year to inform the optimal dose and show how BGE-102 could affect a range of metabolic and inflammatory markers.

Kristen Fortney, Ph.D., CEO and co-founder of BioAge

With a strong cash position, we are well positioned to advance BGE-102 and our apelin and other programs.

Kristen Fortney, Ph.D., CEO and co-founder of BioAge

Not in the filing

stated, not guessed
  • Total revenue separate from collaboration revenue
  • Gross profit and gross margin
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Share repurchases
  • Dividends
  • Non-GAAP financial measures
  • Financial revenue guidance
  • Gross-margin guidance
  • Operating-expense guidance
  • Tax-rate guidance
  • Previous-release outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readBIOA · Second Quarter 2026 · ended June 30, 2026

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

→Mixed quarter

BioAge advanced BGE-102 into Phase 2 and reported a substantial cash position, while research and development expense and net loss increased from the prior-year period.

Revenue
$2.4M

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Collaboration revenueother$2.4M––
Research and development expensesother$24.4M–$4.6 million increase
General and administrative expensesother$7.4M–$0.1 million increase
Net lossother$26.1M––
Net loss per weighted-average common share outstanding, basic and dilutedother$0.58 per weighted-average common share outstanding, basic and diluted––

second half of 2026; mid-2026; mid-2027; by year-end 2026; through 2029 outlook

  • Notetopline data anticipated in the second half of 2026
  • NoteThe Company plans to initiate QUELL-DME, a Phase 1b/2a proof-of-concept trial of BGE-102 in patients with diabetic macular edema, in mid-2026; results are anticipated in mid-2027.
  • NoteThe Company intends to file its first IND for an APJ program by year-end 2026.
  • NoteBased on the Company’s current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.

What drove it

  • In June 2026, BioAge announced that the first participant was dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102, its oral, brain-penetrant NLRP3 inhibitor, measuring inflammatory and cardiometabolic biomarkers.
  • QUELL-CV is a randomized, double-blind, placebo-controlled trial evaluating three once-daily oral doses of BGE-102 (30 mg, 60 mg, and 90 mg) against placebo in approximately 160 adults with obesity and elevated baseline inflammation.
  • The primary endpoint is percent change from baseline in hsCRP, a pharmacodynamic measure of NLRP3 pathway inhibition, over 12 weeks of dosing.
  • BGE-102 achieved up to 98% suppression of IL-1β at trough in an ex vivo whole-blood assay, along with median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily.
  • BGE-102 was well tolerated across all dose levels evaluated, with no serious adverse events, no treatment-emergent adverse events leading to discontinuation, and no clinically meaningful changes in vital signs, ECGs, or laboratory values.
  • The $4.6 million increase in research and development expenses was primarily attributable to a $7.9 million increase in direct costs related to BioAge’s BGE-102 program associated with the initiation of QUELL-CV, start-up costs related to the planned initiation of QUELL-DME, licensing fees, and drug-product manufacturing.
  • The research and development expense increase was further driven by a $1.5 million increase in personnel-related expenses and a $0.3 million increase in allocated facility and other expenses, partially offset by a $3.3 million decrease in direct costs for other programs and a $1.9 million decrease in azelaprag direct costs following termination of its development in January 2025.
  • BioAge's multi-year research collaboration with Novartis continued to advance, with multiple targets under evaluation, and the Company continued to progress its strategic collaboration with Lilly ExploR&D.

Concerns

  • Net loss was $26.1 million for the quarter ended June 30, 2026, compared to a net loss of $21.6 million for the same period in 2025.
  • Research and development expenses were $24.4 million for the quarter ended June 30, 2026, compared to $19.8 million for the same period in 2025.
  • QUELL-DME remains planned to initiate in mid-2026, with results anticipated in mid-2027.
  • The filing identifies risks associated with clinical trials, including the ability to adequately manage clinical activities for BGE-102 and APJ programs, and unexpected concerns that may arise from additional data or analysis obtained during clinical trials.

What to watch

  • Topline QUELL-CV data anticipated in the second half of 2026.
  • Initiation of QUELL-DME in mid-2026 and results anticipated in mid-2027.
  • The Company’s intended filing of its first IND for an APJ program by year-end 2026.
  • Dose selection for further BGE-102 development from the QUELL-CV dose-response characterization.

Balance sheet and cash flow

  • As of June 30, 2026, BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities.
  • Based on the Company’s current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.

Analysis

BioAge reported collaboration revenue of $2.4 million for each of the quarters ended June 30, 2026 and 2025. The company remains a clinical-stage biopharmaceutical business, and the release centered on development progress rather than commercial revenue growth. Its principal advance was dosing the first participant in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 in approximately 160 adults with obesity and elevated baseline inflammation.

Development spending increased as BGE-102 moved into broader clinical execution. Research and development expenses were $24.4 million, compared with $19.8 million in the prior-year period, with the stated increase primarily tied to BGE-102 direct costs, including QUELL-CV initiation, QUELL-DME start-up costs, licensing fees, and drug-product manufacturing. The company also cited higher personnel-related and allocated facility costs. These increases were partly offset by lower direct costs for other programs and lower azelaprag direct costs following termination of that development program in January 2025.

General and administrative expenses were $7.4 million, compared with $7.3 million in the prior-year period. Net loss was $26.1 million, compared with $21.6 million, while net loss per weighted-average common share outstanding, basic and diluted, was $0.58 compared with $0.60. The reported loss expansion coincided with increased BGE-102 investment and did not reflect a change in reported collaboration revenue.

The clinical data and milestones are the central operating focus. BioAge stated that Phase 1 BGE-102 data showed up to 98% suppression of IL-1β at trough and median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily. QUELL-CV is evaluating 30 mg, 60 mg, and 90 mg once-daily doses against placebo, with percent change from baseline in hsCRP over 12 weeks as the primary endpoint. Topline data are anticipated in the second half of 2026, making this readout the near-term clinical catalyst identified in the filing.

Liquidity supports the planned development schedule. BioAge had approximately $381.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and estimated those resources would fund operations and capital expenses through 2029. The company also plans to initiate QUELL-DME in mid-2026, expects results in mid-2027, and intends to file its first IND for an APJ program by year-end 2026. Execution against these milestones, particularly the QUELL-CV readout and BGE-102 dose selection, will determine the next stage of pipeline development.

Management, verbatim

Our Phase 1 data show that BGE-102 is a potential best-in-class NLRP3 inhibitor: a well-tolerated once-daily pill that delivered up to 98% suppression of IL-1β and brought hsCRP down to normal levels in most participants. We have dosed the first participant in QUELL-CV, our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk, with topline data anticipated in the second half of 2026. We also plan to start a second proof-of-concept trial this year in diabetic macular edema. These studies will test the broad potential of NLRP3 inhibition across inflammasome-driven diseases, and we are actively evaluating additional indications where this mechanism can deliver meaningful benefit. With a strong cash position, we are well positioned to advance BGE-102 across multiple opportunities and continue progressing the broader BioAge pipeline.

Kristen Fortney, Ph.D., CEO and co-founder of BioAge

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue by operating segment
  • Gross profit
  • Gross margin
  • Operating income or loss
  • Income tax expense or benefit
  • Tax rate
  • Non-GAAP financial measures
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt
  • Share repurchases
  • Dividends
  • Prior-quarter comparisons for reported financial metrics
  • Financial revenue, gross margin, operating expense, or tax-rate guidance
  • Prior outlook for comparison with reported results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BIOA earnings dates

When is BioAge Labs's next earnings date?
AlphAI has no date for BIOA yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.